400-0512-686
Cardiac disease diagnosis

cTnI/H-FABP Quantitative Test Kit

Time-Resolved Fluorescent Immunochromagraphic Assay

【General Information】

1.Method: Time-resolved Fluorescent Immunochromatographic Method;

2.Bio-marker tested: cardiac troponin I (cTnI) and Heart fatty-acid binding protein (H-FABP);

3.Clinical Sample: whole blood, serum or plasma;

4.Other Specifications: in vitro, quantitative test;

【Clinical significance】

1. Assess infarct size and ACS risks;

2. Bio-marker for monitoring the treatment of AMI;

3.Diagnosis of acute myocardial infarction;

4.15-20 times more cardiac specific than myoglobin;

5.Diagnosis of pulmonary embolism (PE), coronary artery bypass surgery (CABG) and cerebrovascular disease;

【Advantages】

1. Advanced: time-resolved fluorescence immunoassay quantitative chromatography;

2. Quantitative: quantitative detection of cardiac troponin I (cTnI) and Heart fatty-acid binding protein (H-FABP);

3. Accurate: well correlated with imported chemiluminescence reagent (r> 0.975) ;

4. High sensitivity: lower detection limit <0.05 ng/mL (cTnI) and <1.0 ng/mL (H-FABP);

5. Simple: simple operation, suitable for bedside detection;

6. Widely applicable : outpatient laboratory, emergency laboratory, medical center, cardiology, ICU, and etc;




Top

Earlier
April 2014

Lumigenex receives CFDA approval for four POCT immunoassay kits to help physicians quickly and accurately diagnose heart diseases.

March 2014

Lumigenex receives CFDA approval for five immunoassay reagents adaptable to most chemical analyzers.

February 2014

Lumigenex received CFDA approval for time-resolved fluorescence immunochromatographic analyzer.

January 2014

Dr. He Aimin was named "National Thousand Talents Program"

December 2013

Lumigenex access to "high-tech enterprises in Jiangsu Province" title.

September 2013

Lumigenex passed The first Food and Drug Administration by the Suzhou Municipal Quality Management System Assessment.